Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA covers the month of October 2006. The report primarily discloses a new strategic sourcing and supply agreement entered into by the company's North American subsidiary, Fresenius Medical Care Holdings Inc. (FMC-NA), with Amgen USA, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the announcement of a commercial agreement rather than financial performance results.
Material Changes
The primary material change is the execution of a new sourcing and supply agreement with Amgen, effective October 1, 2006, replacing the previous product purchase agreement. Key terms include:
- Duration: The agreement runs from October 1, 2006, to December 31, 2011.
- Scope: Amgen will supply FMC-NA's commercial requirements in the United States and Puerto Rico for erythropoiesis stimulating proteins (EPOGEN and Aranesp) for dialysis patients.
- Exclusivity: Amgen is designated as the sole supplier of these products for use with dialysis patients in the U.S.
- Collaboration: The companies will explore collaborations to develop new product formulations to enhance standards of care.
Guidance, Outlook, and Risks
Management Commentary: CEO Dr. Ben Lipps stated the selection of Amgen was based on over ten years of demonstrated clinical efficacy and safety, which has led to significant clinical outcome improvements in anemic dialysis patients. The company emphasizes a shared commitment to developing new therapies for end-stage renal disease.
Risks and Contingencies: The release includes standard forward-looking statement disclaimers. Actual results could differ materially due to changes in business, economic, and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.
Investor Verification Checklist
- Verify the specific pricing terms and volume commitments within the new Amgen agreement, as these are not disclosed in the text.
- Assess the potential impact of the agreement on the company's cost of goods sold and gross margins for the North American segment.
- Monitor the progress of the announced collaboration on new product formulations.
- Review the company's most recent Form 20-F for detailed financial metrics and liquidity positions not included in this 6-K.